[1] 张露,范志芳,刘殿武,等.1990~2016年中国乙型肝炎引起的肝硬化及其他慢性肝病疾病负担变化趋势分析.中华流行病学杂志,2020,41(2):173-177. [2] 徐京杭, 于岩岩, 徐小元. 肝硬化研究进展和展望. 中华肝脏病杂志, 2021, 29(2):108-110. [3] Campbell KA, Trivedi HD, Chopra S. Infections in cirrhosis: a guide for the clinician. Am J Med, 2021, 134(6):727-734. [4] Huh J, Ham SJ, Cho YC, et al. Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials. BMC Med Imaging, 2019, 19(1):89-97. [5] Wu Z, Cheng ZL, Yi ZL, et al. Assessment of nonalcoholic fatty liver disease in rats using quantitative dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2017, 45(5):1485-1493. [6] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版).中华传染病杂志,2019,37(12):711-736. [7] 黎金葵, 黄宏亮, 朱袁慧, 等. 影像学方法诊断肝硬化门静脉高压的研究进展. 中华肝脏病杂志, 2021, 29(12):1224-1228. [8] 黄登, 曹君贵, 叶航羊,等. 肝硬化门静脉高压血流动力学紊乱发生及发展机制. 中华消化外科杂志, 2021, 20(10):1117-1122. [9] Schwope RB, Katz M, Russell T, et al. The many faces of cirrhosis. Abdom Radiol (NY), 2020, 45(10):3065-3080. [10] Tran A, Koh TS, Prawira A, et al. Dynamic contrast-enhanced magnetic resonance imaging as imaging biomarker for vascular normalization effect of infigratinib in high-fgfr-expressing hepatocellular carcinoma xenografts. Mol Imaging Biol, 2021, 23(1):70-83. [11] Lee JH, Yoo GS, Yoon YC, et al. Diffusion-weighted and dynamic contrast-enhanced magnetic resonance imaging after radiation therapy for bone metastases in patients with hepatocellular carcinoma. Sci Rep, 2021, 11(1):10459-10473. [12] Stocker D, Hectors S, Bane O, et al. Dynamic contrast-enhanced MRI perfusion quantification in hepatocellular carcinoma: comparison of gadoxetate disodium and gadobenate dimeglumine. Eur Radiol, 2021, 31(12):9306-9315. [13] Tamada D, Kromrey ML, Ichikawa S, et al. Motion artifact reduction using a convolutional neural network for dynamic contrast enhanced MR imaging of the liver. Magn Reson Med Sci, 2020, 19(1):64-76. [14] Han T, Duan Q, Yang R, et al. Monitoring the therapeutic efficacy of CA4P in the rabbit VX2 liver tumor using dynamic contrast-enhanced MRI. Diagn Interv Radiol, 2021, 27(5):587-594. [15] Luo J, Zhou K, Zhang B, et al. Intravoxel incoherent motion diffusion-weighted imaging for evaluation of the cell density and angiogenesis of cirrhosis-related nodules in an experimental rat model: comparison and correlation with dynamic contrast-enhanced MRI. J Magn Reson Imaging, 2020, 51(3):812-823. [16] Liao YS, Lee LW, Yang PH, et al. Assessment of liver cirrhosis for patients with Child's a classification before hepatectomy using dynamic contrast-enhanced MRI. Clin Radiol, 2019, 74(5):407-413. [17] Yoon JH, Lee JM, Yu MH, et al. Simultaneous evaluation of perfusion and morphology using GRASP MRI in hepatic fibrosis. Eur Radiol, 2022, 32(1):34-45. [18] Hectors SJ, Bane O, Kennedy P, et al. Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen. Eur Radiol, 2021, 31(7):4804-4812. [19] Wagner M, Hectors S, Bane O, et al. Noninvasive prediction of portal pressure with MR elastography and DCE-MRI of the liver and spleen: Preliminary results. J Magn Reson Imaging, 2018, 48(4):1091-1103. [20] Bayle M, Clerc-Urmès I, Ayav A, et al. Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings. Abdom Radiol (NY), 2019, 44(1):85-94. |